SecBot SecBot

DAWN

Day One Biopharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001845337 Biotech & Drug Discovery
No price
Median target
$21.50
range $21.50–21.50
Insider net
$0
no open-market trades · since Apr 23
New fund stakes
0
Q2 2026 13F · 29 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 5 reports · latest
Balance 0 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 5/5

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Apr 23. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 29 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.190 → −$0.172 over 90 days. 1 up, 3 down in 30 days.

Who's buying

13F· Q2 2026
0
new positions
29
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Mar 2026
Recent actions
DateFirmActionRating
Mar 11, 2026JP Morgan
DOWNGRADE
DOWNGRADENeutral
Mar 10, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Mar 9, 2026Wedbush
DOWNGRADE
DOWNGRADENeutral
Mar 6, 2026Jones Trading
DOWNGRADE
DOWNGRADEHold
Mar 6, 2026Needham
DOWNGRADE
DOWNGRADEHold
Feb 25, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · since Apr 23
DateInsiderTypeValue
Apr 23, 2026
Grossman William
Director
Apr 23, 2026
TO ISSUER32,335 sh
Apr 23, 2026
Merendino Lauren
Chief Commercial Officer
Apr 23, 2026
TO ISSUER18,978 sh
Apr 23, 2026
Merendino Lauren
Chief Commercial Officer
Apr 23, 2026
TO ISSUER60,157 sh
Apr 23, 2026
Merendino Lauren
Chief Commercial Officer
Apr 23, 2026
TO ISSUER330,200 sh
Apr 23, 2026
Nicholson Garry A
Director
Apr 23, 2026
TO ISSUER33,900 sh
Apr 23, 2026
Nicholson Garry A
Director
Apr 23, 2026
TO ISSUER15,000 sh
Apr 23, 2026
Grossman William
Director
Apr 23, 2026
TO ISSUER66,660 sh
Apr 23, 2026
Garland J. Scott
Director
Apr 23, 2026
TO ISSUER48,072 sh

Earnings setup

Estimates
−$0.17
EPS estimate, this quarter
+10%
estimate change, 90 days
1↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.17-$0.28–-$0.09-6.1%$54.3M
Next Q-$0.16-$0.28–-$0.03-11.5%$57.1M
Next FY-$0.04-$0.46–$0.35-206.0%$308.1M
Current FY-$0.76-$1.76–-$0.16-29.5%$240.4M
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 28, 2026 Earnings calendar
DAWN Q3 2026 Earnings Scheduled · 2026-10-28
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO · EXIT
0 shares ($0.00)
May 4, 2026 SEC
Day One Biopharmaceuticals filed Form 15 to terminate its SEC registration and suspend reporting obligations…
15-12G · Impact 5/10
Apr 23, 2026 SEC
Nasdaq has filed Form 25 to delist Day One Biopharmaceuticals (DAWN) common stock, effective immediately, following…
25-NSE · Impact 9/10
Apr 23, 2026 SEC
Day One Biopharmaceuticals (DAWN) was acquired by Servier Pharmaceuticals in an all-cash transaction valued at $2.5…
8-K · Impact 9/10
Apr 23, 2026 Insider
Grossman William disposed of 32,335 shares
Director
Apr 23, 2026 Insider
Merendino Lauren disposed of 18,978 shares
Chief Commercial Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

5 filings · 1 press release · 1 bullish · 0 bearish · 4 neutral
All DAWN filing & press-release reports (6)